Royalty Pharma (RPRX) Receivables - Other (2020 - 2023)

Royalty Pharma has reported Receivables - Other for 4 years, with the latest figure at $14.2 million in Q4 2023.

• Quarterly Receivables - Other fell 15.38% year-over-year to $14.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $14.2 million (down 15.38% YoY) and the FY2023 annual result came in at $14.2 million, down 15.38% from the prior year.
• Receivables - Other eased to $14.2 million in Q4 2023 per RPRX's latest filing, from $16.4 million in the prior quarter.
• Over five years, Receivables - Other peaked at $59.7 million in Q3 2021 and troughed at $14.2 million in Q4 2023.
• A 4-year average of $29.3 million and a median of $25.2 million in 2020 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2021 and 2022: Receivables - Other jumped 84.29% in 2021, then slumped 73.66% in 2022.
• Over 4 years, Receivables - Other stood at $32.4 million in 2020, then surged by 64.61% to $53.3 million in 2021, then sank by 68.42% to $16.8 million in 2022, then retreated by 15.38% to $14.2 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $14.2 million, $16.4 million, and $16.4 million for Q4 2023, Q3 2023, and Q2 2023 respectively.